An Update on ACA Medicaid Expansion: What to Watch in North Carolina and Beyond
This policy watch examines the implications of North Carolina's Medicaid expansion as well as key issues to watch there and across other states.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This policy watch examines the implications of North Carolina's Medicaid expansion as well as key issues to watch there and across other states.
The number and share of people without insurance grew in 2024, increasing for the first time since 2019, according to KFF's analysis of data from the American Community Survey (ACS). This issue brief describes trends in health coverage in 2024, examines the characteristics of the uninsured population , and summarizes the access and financial implications of not having coverage.
The brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
This fact sheet examines the U.S. government’s role in family planning and reproductive health (FP/RH) worldwide.
Among women ages 18-35 with a clinical visit in the past two years, more than four in 10 (46%) report experiencing a negative interaction with a health care provider, according to a new analysis of 2022 KFF Women’s Health Survey (WHS) data. These interactions included a provider either dismissing patients’ concerns, assuming something about them without asking, believing they were lying, blaming them for their health problems, or discriminating against them because of their age,…
This Health Policy 101 chapter outlines the U.S. government's historical efforts in global health, which aim to improve health in low- and middle-income countries. While the U.S. has been engaged in international health activities for over a century and has historically been the largest funder and implementer of global health programs worldwide, it is currently undergoing a fundamental shift, with a significantly reduced footprint and role. Key issues addressed include the future direction of U.S.…
This timeline offers a historical view of significant U.S. federal policies and events spanning the early 1800s to today that have influenced present-day health disparities. It covers policies that directly impacted health coverage and access to care, relevant events in medicine, social and economic policies and developments that influence health, and efforts to tackle inequalities.
The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including a number of changes to the Medicare Part D drug benefit. This brief provides an overview of the Part D benefit design and Part D enrollee cost-sharing requirements in 2023 and changes coming in 2024 and 2025.
This brief examines the final CMS regulations governing prior authorization in Medicare Advantage, Marketplace, Medicaid, and other plans, how they might address some current consumer concerns, and some issues that remain.
The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since…
© 2026 KFF